- Analysis of a multicenter database suggests that suppression of thyrotropin/thyroid-stimulating hormone (TSH) is not associated with improved PFS in patients with intermediate- or high-risk differentiated thyroid cancer (DTC).
Why this matters
- There are conflicting data on the association between TSH suppression and patient outcomes.
- 33.8% of patients experienced disease progression, and 3.9% died.
- TSH suppression was not significantly associated with PFS at 1.5 years (P=.41), 3 years (P=.51), or 5 years (P=.64).
- TSH suppression was not significantly associated with OS at 1.5 years (P=.69) or 5 years (P=.52).
- Nonsuppressed TSH was associated with longer OS at 3 years (moderately suppressed/low-normal vs suppressed [HR, 0.10; P=.03]; low-normal/elevated vs suppressed [HR, 0.10; P=.03]).
- 867 patients with intermediate- or high-risk DTC treated with total thyroidectomy and radioactive iodine as well as levothyroxine therapy for TSH suppression were analyzed for associations between levels of TSH suppression and PFS.
- Funding: NIH.
- Retrospective study.